What Is GxP? GMP, GLP, GCP and GDP Explained
GxP is shorthand for the "good practice" rules that govern regulated life science work: good manufacturing practice (GMP), good laboratory practice (GLP), good clinical practice (GCP), good distribution practice (GDP) and others. The "x" is a placeholder for whichever activity you're doing. GxP isn't a single regulation. It's a family of separate requirements, each with its own legal source, scope and inspectors.
That distinction matters in practice. Most GxP questions inside a company aren't "what does it stand for" but "which of these apply to us, and where exactly is that written down?" This guide answers both: what each GxP covers, the primary source behind it, a five-question check for working out which ones apply to your operation, and the controls they all share.
What does GxP mean?
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) gives a clear working definition in its GXP Data Integrity Guidance and Definitions (March 2018): GXP is "Good 'X' Practice where 'X' is used as a collective term for" good distribution practice, good clinical practice, good laboratory practice, good manufacturing practice and good pharmacovigilance practice.
Two things follow from that definition. First, GxP describes a category, not a document you can download. Second, being "GxP compliant" only means something once you name the specific practices and regulations in scope. A contract lab running nonclinical safety studies and a wholesale distributor storing finished medicines are both "GxP" businesses, but they answer to almost entirely different rules.
The main GxPs and where each one comes from
The table below maps each practice to the activity it governs and a primary source to start from. It isn't a complete list of every applicable rule, and other jurisdictions have their own equivalents, but it shows where the requirements actually live.
| Practice | What it governs | Primary source to start from |
|---|---|---|
| Good laboratory practice (GLP) | Nonclinical laboratory studies (for example, animal safety and toxicology studies) that support applications to FDA | 21 CFR Part 58 (FDA) |
| Good manufacturing practice (GMP) | Manufacturing, processing, packing and holding of medicinal products | 21 CFR Part 211 for finished pharmaceuticals (FDA); EudraLex Volume 4 (EU GMP guidelines) |
| Good clinical practice (GCP) | Interventional clinical trials of investigational products involving human participants | ICH E6(R3) (international guideline) |
| Good distribution practice (GDP) | Wholesale distribution of medicinal products | EU Guidelines on Good Distribution Practice of Medicinal Products for Human Use, OJ C 343/1, 2013 (see EMA: Good distribution practice) |
| Good pharmacovigilance practice (GPvP) | Monitoring the safety of medicines after they reach patients | Listed as a GXP area in the MHRA GXP data integrity guidance |
| Electronic records (applies across the GxPs) | Computerized systems that create or hold GxP records | 21 CFR Part 11 (FDA); EU GMP Annex 11, Computerised Systems (EudraLex Volume 4) |
Good laboratory practice (GLP)
FDA's GLP regulation, 21 CFR Part 58, covers "nonclinical laboratory studies that support or are intended to support applications for research or marketing permits" for FDA-regulated products. The applications it lists include investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs) and premarket approval applications (PMAs) for devices. GLP is about the integrity of the study: protocols, study conduct, raw data and the final report.
Good manufacturing practice (GMP)
For finished drugs in the US, 21 CFR Part 211 sets out "the minimum current good manufacturing practice for preparation of drug products." It requires a quality control unit (§211.22) and review and approval of production and control records by that unit (§211.192). In the EU, the GMP guidelines and their annexes sit in EudraLex Volume 4. For a practical walkthrough, see our guide to GMP guidelines.
Good clinical practice (GCP)
GCP is defined internationally by ICH E6. The current revision, ICH E6(R3), describes GCP as "an international, ethical, scientific and quality standard" for trials involving human participants, and applies to "interventional clinical trials of investigational products" intended for submission to regulators. Its principles and Annex 1 reached ICH Step 4 on 6 January 2025, Annex 2 followed on 3 June 2026, and ICH published a consolidated final version on 16 June 2026. Each regulator adopts the guideline on its own timeline, so check what your authority currently expects.
Good distribution practice (GDP)
In the EU, GDP "describes the minimum standards that a wholesale distributor must meet" (EMA), and wholesale distributors must comply with it to hold a wholesale distribution authorization. The current guidelines for human medicines have applied since 24 November 2013 (OJ C 343/1).
Three common GxP mix-ups
Several of the pages that rank for this topic blur the lines between practices. These are the ones worth getting right:
- GDP means distribution, not documentation. "Good documentation practice" is sometimes abbreviated GDP or GDocP, but in the MHRA definition GDP is good distribution practice. When a regulator or auditor says GDP, they mean the supply chain. Documentation expectations are built into every GxP rather than standing as a separate regulation.
- GLP and GCP aren't subsets of GMP. They govern different activities (nonclinical studies and human trials) under different rules: 21 CFR Part 58 and ICH E6, not 21 CFR Part 211.
- There's no single "GxP certificate". Because GxP is a collective term, you show compliance by meeting each applicable regulation, typically checked during regulatory inspections. Be precise when a customer or supplier questionnaire asks whether you are "GxP certified": name the practices and regulations you actually operate under.
Which GxPs apply to you? A five-question check
Work through these questions for each site and each product. Answer them for what you actually do, not for what your customers do.
- Do you run nonclinical laboratory studies that support an application to a regulator? If yes, GLP is in scope (21 CFR Part 58 in the US).
- Do you manufacture, process, pack, label or hold medicinal products or their components? If yes, GMP is in scope.
- Do you sponsor, run, or provide services to interventional clinical trials? If yes, GCP is in scope for those activities.
- Do you store, move or wholesale medicines? If yes, check GDP, particularly for EU distribution.
- Do any of your computerized systems create, change, store or report records that a GxP regulation requires? If yes, those systems are GxP systems, and Part 11 (US) and Annex 11 (EU) expectations apply to them.
Most companies answer "yes" to more than one. A small biotech might have GLP studies at a contract lab, GCP trials through a CRO and GMP clinical supply at a contract manufacturer. Write the answers down as a scope statement in your quality manual. It becomes the reference for training plans, supplier qualification and which procedures you need.
What every GxP has in common
The rules differ by activity, but the themes are consistent: qualified people following written procedures, records that can be trusted, and quality oversight that is independent of the work being done. The table maps some of these shared expectations to the text behind them.
| Shared expectation | Where it shows up |
|---|---|
| Independent quality oversight | 21 CFR 211.22: "There shall be a quality control unit"; §211.192: production and control records reviewed and approved by that unit |
| Trustworthy data (ALCOA+) | MHRA GXP data integrity guidance: data should be Attributable, Legible, Contemporaneous, Original and Accurate, plus Complete, Consistent, Enduring and Available |
| Audit trails on electronic records | 21 CFR 11.10(e): secure, computer-generated, time-stamped audit trails |
| Validated computerized systems | 21 CFR 11.10(a): validation of systems |
| Trained, qualified people | 21 CFR 11.10(i): education, training and experience of the people who develop, maintain or use electronic systems |
| Controlled documents and change control | 21 CFR 11.10(k): controls over systems documentation, including revision and change control |
On ALCOA+, the MHRA notes that the "+" adds emphasis and that there is no difference in expectations between ALCOA and ALCOA+. In practice, that means every GxP record, paper or electronic, should show who did what and when, be readable for as long as you keep it, and stay complete and unaltered unless a change is recorded.
GxP systems and electronic records
A "GxP system" is any system whose records a GxP regulation relies on: a LIMS holding lab results, an ERP recording batch release, or a QMS holding SOPs, deviations and training records. Under 21 CFR Part 11, the rule applies to "records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted, under any records requirements set forth in agency regulations." In other words, Part 11 attaches to records the other GxP rules already require. It doesn't create a separate category of records.
Section 11.10 lists the controls FDA expects for closed systems, including validation, accurate and complete copies, record protection, limited system access, audit trails, operational, authority and device checks, training, written accountability policies, and control over system documentation. EU GMP Annex 11 covers computerised systems for EU GMP. Our guide to 21 CFR Part 11 and QMS validation walkthrough go deeper on both.
How an eQMS supports GxP work
The shared expectations above are where paper systems and disconnected spreadsheets struggle most: proving which SOP version was in effect, showing that the people who did the work were trained on it, and following a deviation through to its corrective action. Isolocity's life science QMS is built for ISO 13485, MDSAP and GxP standards, and is compliant with FDA 21 CFR Part 11 and Annex 11.
In the platform, documents are revision-controlled, with past revisions available to view, and document management includes change control, four-stage approvals, links to training and an audit trail. The CAPA module covers CAPA, deviations, nonconformances, out-of-specification results and customer complaints, and the training module keeps employee training records and can be added to documents or CAPA. For GLP work specifically, Isolocity also offers a lab quality management system.
Whatever system you use, you remain responsible for validating it for your intended use and for the procedures around it. If you're comparing options, our article on choosing a pharmaceutical QMS sets out the main decision points.
FAQ
What does GxP stand for?
GxP stands for "good x practice", where x is the regulated activity: manufacturing (GMP), laboratory (GLP), clinical (GCP), distribution (GDP) or pharmacovigilance (GPvP), among others. The MHRA uses "GXP" as a collective term for these practices.
What is GxP in pharma?
In the pharmaceutical industry, GxP covers the full life cycle of a medicine: nonclinical studies (GLP), clinical trials (GCP), manufacturing (GMP), distribution (GDP) and post-market safety monitoring (GPvP). Each stage has its own regulations and inspectors.
What is GxP compliance?
GxP compliance means meeting every good practice regulation that applies to your activities and being able to show it through records during an inspection or audit. Start by defining which practices are in scope (see the five-question check above), then map each one to your procedures.
What is a GxP system?
A GxP system is any computerized system that creates, modifies, stores or reports records required by a GxP regulation. In the US, 21 CFR Part 11 sets the controls for those electronic records, and in the EU, EU GMP Annex 11 covers computerised systems.
What is GxP data?
GxP data is any data used to meet a GxP requirement or to make a GxP decision, such as batch records, lab results, trial data or training records. Regulators expect it to meet the ALCOA+ principles described in the MHRA's GXP data integrity guidance.
Conclusion
GxP is easier to manage once you stop treating it as one rulebook. Name the practices that apply to each activity, tie each one to its primary source, and build your procedures around the expectations they share: quality oversight, trustworthy records, controlled documents and trained people. If you'd like to see how Isolocity handles document control, CAPA and training in one place, book a demo.






